我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
47
25 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
24
51.1%
已完成
5
10.6%
尚未招募
1
2.1%
招募中
17
36.2%
暂无批准数据
- UCLA's Arjan Gower received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to launch a multi-institutional clinical trial testing zipalertinib. - The investigational drug targets specific EGFR mutations, including Exon 20 insertions, which drive cancer growth and resist standard treatments. - This funding represents a significant investment in developing targeted therapies for previously difficult-to-treat EGFR-mutated cancers. - The multi-institutional approach suggests broad clinical collaboration to evaluate this novel targeted therapy's potential.
